[{"arm_notes": "", "treatment_id": null, "treatment_name": "23279;26532;11241;33872;23484;1798;22178;11957;10505;14907;3421;1811;22124;1812;Participants will be divided into 2 groups randomized 1:1; randomly. In this way; they will receive a sequential inclusion number from an electronically drawn number table and will receive the proposed treatment.20 participants allocated to Group 1 - Control - Inhalation with 0.9% saline solution applied 4-4 hours; for seven days.20 participants allocated to Group 2 - High molecular weight inhalational heparin (HMWH) (2.5mg/mL 0.9% SF); who will receive care with the experimental treatment with inhaled HAPM applied in 4-4 hours; for seven days.Follow-up clinical visits; full physical examination and laboratory exams will be performed on both arms for the first seven days after the patient's inclusion in the study groups. The clinical visits and medical examinations; including viital signs will be performed daily during the study period; which include the day of inclusion (visit 1); seven days of treatment (visits 2 to 8) and a final visit (visit 9). The frequency will be as follows:Clinical visit and physical examination (visits 1 to 9);RT-PCR for COVID-19 (visits 1;3; 6; 8; 9);Computed tomography of the chest for pulmonary evaluation (visits 1 and 9);Complete blood cell count (visits 1;3; 6; 8; 9);D-dimer (visits 1;3; 6; 8; 9);Complete coagulogram (visits 1;3; 6; 8; 9);Urea and creatinine (visits 1;3; 6; 8; 9);Fasted blood glucose (visits 1;3; 6; 8; 9);C-reactive protein (CRP) (visits 1;3; 6; 8; 9);Arterial blood gas analysis (visits 1.3; 6; 8; 9);Amylase (visits 1;3; 6; 8; 9).", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group 1 - Control - Inhalation with 0.9% saline solution applied 4-4 hours; for seven days.20 participants allocated to", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group 2 - High molecular weight inhalational heparin (HMWH) (2.5mg/mL 0.9% SF); who will receive care with the experimental treatment with inhaled HAPM applied in 4-4 hours; for seven days.Follow-up clinical visits; full physical examination and laboratory exams will be performed on both arms for the first seven days after the patient's inclusion in the study groups. The clinical visits and medical examinations; including viital signs will be performed daily during the study period; which include the day of inclusion (visit 1); seven days of treatment (visits 2 to 8) and a final visit (visit 9). The frequency will be as follows:Clinical visit and physical examination (visits 1 to 9);RT-PCR for COVID-19 (visits 1;3; 6; 8; 9);Computed tomography of the chest for pulmonary evaluation (visits 1 and 9);Complete blood cell count (visits 1;3; 6; 8; 9);D-dimer (visits 1;3; 6; 8; 9);Complete coagulogram (visits 1;3; 6; 8; 9);Urea and creatinine (visits 1;3; 6; 8; 9);Fasted blood glucose (visits 1;3; 6; 8; 9);C-reactive protein (CRP) (visits 1;3; 6; 8; 9);Arterial blood gas analysis (visits 1.3; 6; 8; 9);Amylase (visits 1;3; 6; 8; 9).", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "", "treatment_id": 2394, "treatment_name": "High molecular weight inhalation heparin", "treatment_type": "Coagulation modifiers", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]

[{"arm_notes": "", "treatment_id": null, "treatment_name": "Participants will be divided into 2 groups randomized 1:1; randomly. In this way; they will receive a sequential inclusion number from an electronically drawn number table and will receive the proposed treatment.20 participants allocated to Group 1 - Control - Inhalation with 0.9% saline solution applied 4-4 hours; for seven days.20 participants allocated to Group 2 - High molecular weight inhalational heparin (HMWH) (2.5mg/mL 0.9% SF); who will receive care with the experimental treatment with inhaled HAPM applied in 4-4 hours; for seven days.Follow-up clinical visits; full physical examination and laboratory exams will be performed on both arms for the first seven days after the patient's inclusion in the study groups. The clinical visits and medical examinations; including viital signs will be performed daily during the study period; which include the day of inclusion (visit 1); seven days of treatment (visits 2 to 8) and a final visit (visit 9). The frequency will be as follows:Clinical visit and physical examination (visits 1 to 9);RT-PCR for COVID-19 (visits 1;3; 6; 8; 9);Computed tomography of the chest for pulmonary evaluation (visits 1 and 9);Complete blood cell count (visits 1;3; 6; 8; 9);D-dimer (visits 1;3; 6; 8; 9);Complete coagulogram (visits 1;3; 6; 8; 9);Urea and creatinine (visits 1;3; 6; 8; 9);Fasted blood glucose (visits 1;3; 6; 8; 9);C-reactive protein (CRP) (visits 1;3; 6; 8; 9);Arterial blood gas analysis (visits 1.3; 6; 8; 9);Amylase (visits 1;3; 6; 8; 9).;23279;26532;11241;33872;23484;1798;22178;11957;10505;14907;3421;1812;22124;1811", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group 1 - Control - Inhalation with 0.9% saline solution applied 4-4 hours; for seven days.20 participants allocated to", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group 2 - High molecular weight inhalational heparin (HMWH) (2.5mg/mL 0.9% SF); who will receive care with the experimental treatment with inhaled HAPM applied in 4-4 hours; for seven days.Follow-up clinical visits; full physical examination and laboratory exams will be performed on both arms for the first seven days after the patient's inclusion in the study groups. The clinical visits and medical examinations; including viital signs will be performed daily during the study period; which include the day of inclusion (visit 1); seven days of treatment (visits 2 to 8) and a final visit (visit 9). The frequency will be as follows:Clinical visit and physical examination (visits 1 to 9);RT-PCR for COVID-19 (visits 1;3; 6; 8; 9);Computed tomography of the chest for pulmonary evaluation (visits 1 and 9);Complete blood cell count (visits 1;3; 6; 8; 9);D-dimer (visits 1;3; 6; 8; 9);Complete coagulogram (visits 1;3; 6; 8; 9);Urea and creatinine (visits 1;3; 6; 8; 9);Fasted blood glucose (visits 1;3; 6; 8; 9);C-reactive protein (CRP) (visits 1;3; 6; 8; 9);Arterial blood gas analysis (visits 1.3; 6; 8; 9);Amylase (visits 1;3; 6; 8; 9).;23279;26532;11241;33872;23484;1798;22178;11957;10505;14907;3421;1812;22124;1811", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "", "treatment_id": 2394, "treatment_name": "High molecular weight inhalation heparin", "treatment_type": "Coagulation modifiers", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]

[{"arm_notes": "", "treatment_id": null, "treatment_name": "23279;26532;11241;33872;23484;1798;22178;11957;10505;14907;3421;1812;22124;1811;Participants will be divided into 2 groups randomized 1:1; randomly. In this way; they will receive a sequential inclusion number from an electronically drawn number table and will receive the proposed treatment.20 participants allocated to Group 1 - Control - Inhalation with 0.9% saline solution applied 4-4 hours; for seven days.20 participants allocated to Group 2 - High molecular weight inhalational heparin (HMWH) (2.5mg/mL 0.9% SF); who will receive care with the experimental treatment with inhaled HAPM applied in 4-4 hours; for seven days.Follow-up clinical visits; full physical examination and laboratory exams will be performed on both arms for the first seven days after the patient's inclusion in the study groups. The clinical visits and medical examinations; including viital signs will be performed daily during the study period; which include the day of inclusion (visit 1); seven days of treatment (visits 2 to 8) and a final visit (visit 9). The frequency will be as follows:Clinical visit and physical examination (visits 1 to 9);RT-PCR for COVID-19 (visits 1;3; 6; 8; 9);Computed tomography of the chest for pulmonary evaluation (visits 1 and 9);Complete blood cell count (visits 1;3; 6; 8; 9);D-dimer (visits 1;3; 6; 8; 9);Complete coagulogram (visits 1;3; 6; 8; 9);Urea and creatinine (visits 1;3; 6; 8; 9);Fasted blood glucose (visits 1;3; 6; 8; 9);C-reactive protein (CRP) (visits 1;3; 6; 8; 9);Arterial blood gas analysis (visits 1.3; 6; 8; 9);Amylase (visits 1;3; 6; 8; 9).", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group 1 - Control - Inhalation with 0.9% saline solution applied 4-4 hours; for seven days.20 participants allocated to", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group 2 - High molecular weight inhalational heparin (HMWH) (2.5mg/mL 0.9% SF); who will receive care with the experimental treatment with inhaled HAPM applied in 4-4 hours; for seven days.Follow-up clinical visits; full physical examination and laboratory exams will be performed on both arms for the first seven days after the patient's inclusion in the study groups. The clinical visits and medical examinations; including viital signs will be performed daily during the study period; which include the day of inclusion (visit 1); seven days of treatment (visits 2 to 8) and a final visit (visit 9). The frequency will be as follows:Clinical visit and physical examination (visits 1 to 9);RT-PCR for COVID-19 (visits 1;3; 6; 8; 9);Computed tomography of the chest for pulmonary evaluation (visits 1 and 9);Complete blood cell count (visits 1;3; 6; 8; 9);D-dimer (visits 1;3; 6; 8; 9);Complete coagulogram (visits 1;3; 6; 8; 9);Urea and creatinine (visits 1;3; 6; 8; 9);Fasted blood glucose (visits 1;3; 6; 8; 9);C-reactive protein (CRP) (visits 1;3; 6; 8; 9);Arterial blood gas analysis (visits 1.3; 6; 8; 9);Amylase (visits 1;3; 6; 8; 9).", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}, {"arm_notes": "", "treatment_id": 2394, "treatment_name": "High molecular weight inhalation heparin", "treatment_type": "Coagulation modifiers", "pharmacological_treatment": "Pharmacological treatment"}]

[{"arm_notes": "", "treatment_id": null, "treatment_name": "Participants will be divided into 2 groups randomized 1:1; randomly. In this way; they will receive a sequential inclusion number from an electronically drawn number table and will receive the proposed treatment.20 participants allocated to Group 1 - Control - Inhalation with 0.9% saline solution applied 4-4 hours; for seven days.20 participants allocated to Group 2 - High molecular weight inhalational heparin (HMWH) (2.5mg/mL 0.9% SF); who will receive care with the experimental treatment with inhaled HAPM applied in 4-4 hours; for seven days.Follow-up clinical visits; full physical examination and laboratory exams will be performed on both arms for the first seven days after the patient's inclusion in the study groups. The clinical visits and medical examinations; including viital signs will be performed daily during the study period; which include the day of inclusion (visit 1); seven days of treatment (visits 2 to 8) and a final visit (visit 9). The frequency will be as follows:Clinical visit and physical examination (visits 1 to 9);RT-PCR for COVID-19 (visits 1;3; 6; 8; 9);Computed tomography of the chest for pulmonary evaluation (visits 1 and 9);Complete blood cell count (visits 1;3; 6; 8; 9);D-dimer (visits 1;3; 6; 8; 9);Complete coagulogram (visits 1;3; 6; 8; 9);Urea and creatinine (visits 1;3; 6; 8; 9);Fasted blood glucose (visits 1;3; 6; 8; 9);C-reactive protein (CRP) (visits 1;3; 6; 8; 9);Arterial blood gas analysis (visits 1.3; 6; 8; 9);Amylase (visits 1;3; 6; 8; 9).;23279;26532;11241;33872;23484;1798;22178;11957;10505;14907;3421;1812;22124;1811", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group 1 - Control - Inhalation with 0.9% saline solution applied 4-4 hours; for seven days.20 participants allocated to", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group 2 - High molecular weight inhalational heparin (HMWH) (2.5mg/mL 0.9% SF); who will receive care with the experimental treatment with inhaled HAPM applied in 4-4 hours; for seven days.Follow-up clinical visits; full physical examination and laboratory exams will be performed on both arms for the first seven days after the patient's inclusion in the study groups. The clinical visits and medical examinations; including viital signs will be performed daily during the study period; which include the day of inclusion (visit 1); seven days of treatment (visits 2 to 8) and a final visit (visit 9). The frequency will be as follows:Clinical visit and physical examination (visits 1 to 9);RT-PCR for COVID-19 (visits 1;3; 6; 8; 9);Computed tomography of the chest for pulmonary evaluation (visits 1 and 9);Complete blood cell count (visits 1;3; 6; 8; 9);D-dimer (visits 1;3; 6; 8; 9);Complete coagulogram (visits 1;3; 6; 8; 9);Urea and creatinine (visits 1;3; 6; 8; 9);Fasted blood glucose (visits 1;3; 6; 8; 9);C-reactive protein (CRP) (visits 1;3; 6; 8; 9);Arterial blood gas analysis (visits 1.3; 6; 8; 9);Amylase (visits 1;3; 6; 8; 9).;23279;26532;11241;33872;23484;1798;22178;11957;10505;14907;3421;1812;22124;1811", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "", "treatment_id": 2394, "treatment_name": "High molecular weight inhalation heparin", "treatment_type": "Coagulation modifiers", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]

[{"arm_notes": "", "treatment_id": null, "treatment_name": "23279;26532;11241;33872;23484;1798;22178;11957;10505;14907;3421;1812;22124;1811;Participants will be divided into 2 groups randomized 1:1; randomly. In this way; they will receive a sequential inclusion number from an electronically drawn number table and will receive the proposed treatment.20 participants allocated to Group 1 - Control - Inhalation with 0.9% saline solution applied 4-4 hours; for seven days.20 participants allocated to Group 2 - High molecular weight inhalational heparin (HMWH) (2.5mg/mL 0.9% SF); who will receive care with the experimental treatment with inhaled HAPM applied in 4-4 hours; for seven days.Follow-up clinical visits; full physical examination and laboratory exams will be performed on both arms for the first seven days after the patient's inclusion in the study groups. The clinical visits and medical examinations; including viital signs will be performed daily during the study period; which include the day of inclusion (visit 1); seven days of treatment (visits 2 to 8) and a final visit (visit 9). The frequency will be as follows:Clinical visit and physical examination (visits 1 to 9);RT-PCR for COVID-19 (visits 1;3; 6; 8; 9);Computed tomography of the chest for pulmonary evaluation (visits 1 and 9);Complete blood cell count (visits 1;3; 6; 8; 9);D-dimer (visits 1;3; 6; 8; 9);Complete coagulogram (visits 1;3; 6; 8; 9);Urea and creatinine (visits 1;3; 6; 8; 9);Fasted blood glucose (visits 1;3; 6; 8; 9);C-reactive protein (CRP) (visits 1;3; 6; 8; 9);Arterial blood gas analysis (visits 1.3; 6; 8; 9);Amylase (visits 1;3; 6; 8; 9).", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group 1 - Control - Inhalation with 0.9% saline solution applied 4-4 hours; for seven days.20 participants allocated to", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group 2 - High molecular weight inhalational heparin (HMWH) (2.5mg/mL 0.9% SF); who will receive care with the experimental treatment with inhaled HAPM applied in 4-4 hours; for seven days.Follow-up clinical visits; full physical examination and laboratory exams will be performed on both arms for the first seven days after the patient's inclusion in the study groups. The clinical visits and medical examinations; including viital signs will be performed daily during the study period; which include the day of inclusion (visit 1); seven days of treatment (visits 2 to 8) and a final visit (visit 9). The frequency will be as follows:Clinical visit and physical examination (visits 1 to 9);RT-PCR for COVID-19 (visits 1;3; 6; 8; 9);Computed tomography of the chest for pulmonary evaluation (visits 1 and 9);Complete blood cell count (visits 1;3; 6; 8; 9);D-dimer (visits 1;3; 6; 8; 9);Complete coagulogram (visits 1;3; 6; 8; 9);Urea and creatinine (visits 1;3; 6; 8; 9);Fasted blood glucose (visits 1;3; 6; 8; 9);C-reactive protein (CRP) (visits 1;3; 6; 8; 9);Arterial blood gas analysis (visits 1.3; 6; 8; 9);Amylase (visits 1;3; 6; 8; 9).", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "", "treatment_id": 1337, "treatment_name": "Unfractioned heparin", "treatment_type": "Coagulation modifiers", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]

[{"arm_notes": "", "treatment_id": null, "treatment_name": "Participants will be divided into 2 groups randomized 1:1; randomly. In this way; they will receive a sequential inclusion number from an electronically drawn number table and will receive the proposed treatment.20 participants allocated to Group 1 - Control - Inhalation with 0.9% saline solution applied 4-4 hours; for seven days.20 participants allocated to Group 2 - High molecular weight inhalational heparin (HMWH) (2.5mg/mL 0.9% SF); who will receive care with the experimental treatment with inhaled HAPM applied in 4-4 hours; for seven days.Follow-up clinical visits; full physical examination and laboratory exams will be performed on both arms for the first seven days after the patient's inclusion in the study groups. The clinical visits and medical examinations; including viital signs will be performed daily during the study period; which include the day of inclusion (visit 1); seven days of treatment (visits 2 to 8) and a final visit (visit 9). The frequency will be as follows:Clinical visit and physical examination (visits 1 to 9);RT-PCR for COVID-19 (visits 1;3; 6; 8; 9);Computed tomography of the chest for pulmonary evaluation (visits 1 and 9);Complete blood cell count (visits 1;3; 6; 8; 9);D-dimer (visits 1;3; 6; 8; 9);Complete coagulogram (visits 1;3; 6; 8; 9);Urea and creatinine (visits 1;3; 6; 8; 9);Fasted blood glucose (visits 1;3; 6; 8; 9);C-reactive protein (CRP) (visits 1;3; 6; 8; 9);Arterial blood gas analysis (visits 1.3; 6; 8; 9);Amylase (visits 1;3; 6; 8; 9).;23279;26532;11241;33872;23484;1798;22178;11957;10505;14907;3421;1812;22124;1811", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group 1 - Control - Inhalation with 0.9% saline solution applied 4-4 hours; for seven days.20 participants allocated to", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group 2 - High molecular weight inhalational heparin (HMWH) (2.5mg/mL 0.9% SF); who will receive care with the experimental treatment with inhaled HAPM applied in 4-4 hours; for seven days.Follow-up clinical visits; full physical examination and laboratory exams will be performed on both arms for the first seven days after the patient's inclusion in the study groups. The clinical visits and medical examinations; including viital signs will be performed daily during the study period; which include the day of inclusion (visit 1); seven days of treatment (visits 2 to 8) and a final visit (visit 9). The frequency will be as follows:Clinical visit and physical examination (visits 1 to 9);RT-PCR for COVID-19 (visits 1;3; 6; 8; 9);Computed tomography of the chest for pulmonary evaluation (visits 1 and 9);Complete blood cell count (visits 1;3; 6; 8; 9);D-dimer (visits 1;3; 6; 8; 9);Complete coagulogram (visits 1;3; 6; 8; 9);Urea and creatinine (visits 1;3; 6; 8; 9);Fasted blood glucose (visits 1;3; 6; 8; 9);C-reactive protein (CRP) (visits 1;3; 6; 8; 9);Arterial blood gas analysis (visits 1.3; 6; 8; 9);Amylase (visits 1;3; 6; 8; 9).;23279;26532;11241;33872;23484;1798;22178;11957;10505;14907;3421;1812;22124;1811", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]